iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

USFDA issues EIR for Suven Pharmaceuticals' subsidiary; stock skids ~2%

4 Oct 2022 , 02:08 PM

Suven Pharmaceuticals Limited announced that the US Food and Medication Administration (USFDA) has given an EIR for its wholly owned subsidiary Casper Pharma Private Limited, a finished dosage drug Manufacturer for human use.

The pre-approval inspection was conducted between July 25 to July 29, 2022.

Pre-approval Inspections covered three applications: NDA 016084, ANDA 217020, and ANDA 217030.

The inspection concluded with no observation (FDA-483) issued, stated the company.

According to the EIR obtained from the US FDA, the site is recommended for approval of the three NDAs and ANDAs indicated above.

Venkat Jasti, Managing Director of Suven Pharmaceuticals stated, “We are pleased to have completed the first-ever USFDA audit of this plant successfully with Zero observations and now with the receipt of EIR recommending the site.”

At around 2.13 PM, Suven Pharmaceuticals was trading 1.74% lower at Rs435, against previous close of Rs442.70 on NSE. The scrip hit an intraday high and low of Rs449.45 and Rs425 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Pharma Sector News
  • Pharmaceuticals News
  • Suven Pharma Shares
  • Suven Pharma Stock
  • Suven Pharma Updates
  • Suven Pharmaceuticals’
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.